Follicum receives patent approval in China
Follicum AB ("Follicum") today announces that the Chinese Patent Office (SIPO) has granted the company's patent application for stimulation of hair growth.
Thanks to SIPO's grant of patent number ZL 201280049850.X, Follicum has protection in China until 2032. The patent protects the company's peptides in general and for the stimulation of hair growth specifically.
CEO Jan Alenfall’s comments
"China is an important growing future market for Follicum, so this is a very pleasing message. Given the great interest in the company's products in Asia, it is very pleasing to now have a patent in China as well. With the formal approval from China, this patent has been granted in the United States, Europe, Australia, Russia and Hong Kong in addition to Japan. We therefore have very good protection regarding our candidate molecule and additional peptides in significant markets around the world”.
For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: +46 46 19 21 97
This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on the 23th November 2017.
About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, the drug candidate FOL-014 has demonstrated an increase in insulin release in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Aktietorget since 2014. www.follicum.com